These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7751879)

  • 1. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma.
    Nadali G; Vinante F; Stein H; Todeschini G; Tecchio C; Morosato L; Chilosi M; Menestrina F; Kinney MC; Greer JP
    J Clin Oncol; 1995 Jun; 13(6):1355-60. PubMed ID: 7751879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients.
    Zinzani PL; Pileri S; Bendandi M; Buzzi M; Sabattini E; Ascani S; Gherlinzoni F; Magagnoli M; Albertini P; Tura S
    J Clin Oncol; 1998 Apr; 16(4):1532-7. PubMed ID: 9552063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30 ligand in lymphoma patients with CD30+ tumors.
    Younes A; Consoli U; Snell V; Clodi K; Kliche KO; Palmer JL; Gruss HJ; Armitage R; Thomas EK; Cabanillas F; Andreeff M
    J Clin Oncol; 1997 Nov; 15(11):3355-62. PubMed ID: 9363866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis.
    Nadali G; Vinante F; Ambrosetti A; Todeschini G; Veneri D; Zanotti R; Meneghini V; Ricetti MM; Benedetti F; Vassanelli A
    J Clin Oncol; 1994 Apr; 12(4):793-7. PubMed ID: 8151321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
    Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
    Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients.
    Zinzani PL; Bendandi M; Martelli M; Falini B; Sabattini E; Amadori S; Gherlinzoni F; Martelli MF; Mandelli F; Tura S; Pileri SA
    J Clin Oncol; 1996 Mar; 14(3):955-62. PubMed ID: 8622045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-dependent changes of serum soluble CD30 concentration in children.
    Chrul S; Polakowska E
    Pediatr Transplant; 2011 Aug; 15(5):515-8. PubMed ID: 21672104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age.
    Heshmat NM; El-Hadidi ES
    Pediatr Allergy Immunol; 2006 Jun; 17(4):297-303. PubMed ID: 16771784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease.
    Gause A; Pohl C; Tschiersch A; Da Costa L; Jung W; Diehl V; Hasenclever D; Pfreundschuh M
    Blood; 1991 May; 77(9):1983-8. PubMed ID: 1850308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage.
    Pizzolo G; Vinante F; Chilosi M; Dallenbach F; Josimovic-Alasevic O; Diamantstein T; Stein H
    Br J Haematol; 1990 Jun; 75(2):282-4. PubMed ID: 2164839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaplastic large cell lymphoma (CD30+/Ki-1+). Analysis of 35 cases followed at GISL centres.
    Longo G; Federico M; Pieresca C; Avanzini P; Iannitto E; Di Prisco AU; Baldini L; Brugiatelli M; Clò V; Bevini M
    Eur J Cancer; 1995 Oct; 31A(11):1763-7. PubMed ID: 8541096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble CD30: a possible serum tumor marker for primary effusion lymphoma.
    Michai M; Goto H; Hattori S; Vaeteewoottacharn K; Wongkham C; Wongkham S; Okada S
    Asian Pac J Cancer Prev; 2012; 13(10):4939-41. PubMed ID: 23244086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble CD30 and cyclosporine in severe atopic dermatitis.
    Caproni M; Salvatore E; Cardinali C; Brazzini B; Fabbri P
    Int Arch Allergy Immunol; 2000 Apr; 121(4):324-8. PubMed ID: 10828723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD30 molecule (Ki-1 Ag): more than just a marker of CD30+ lymphoma.
    Pizzolo G; Romagnani S
    Haematologica; 1995; 80(4):357-66. PubMed ID: 7590507
    [No Abstract]   [Full Text] [Related]  

  • 16. [Dipeptidyl aminopeptidase-IV as a histochemical marker of differential diagnosis of large cell anaplastic CD30+-lymphoma and Hodgkin's disease].
    Raĭkhlin NT; Bukaeva IA; Probatova NA; Smirnova EA; Pavlovskaia AI; Tupitsyn NN; Sholokhova EN
    Arkh Patol; 2000; 62(4):3-8. PubMed ID: 10971865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome.
    Shulman LN; Frisard B; Antin JH; Wheeler C; Pinkus G; Magauran N; Mauch P; Nobles E; Mashal R; Canellos G
    J Clin Oncol; 1993 May; 11(5):937-42. PubMed ID: 8387578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.
    Hirsch B; Hummel M; Bentink S; Fouladi F; Spang R; Zollinger R; Stein H; Dürkop H
    Am J Pathol; 2008 Feb; 172(2):510-20. PubMed ID: 18187570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary cutaneous CD30 positive T-cell lymphoproliferative disorders with aberrant expression of PAX5: report of three cases.
    Hagiwara M; Tomita A; Takata K; Shimoyama Y; Yoshino T; Tomita Y; Nakamura S
    Pathol Int; 2012 Apr; 62(4):264-70. PubMed ID: 22449230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma.
    Sandlund JT; Pui CH; Santana VM; Mahmoud H; Roberts WM; Morris S; Raimondi S; Ribeiro R; Crist WM; Lin JS
    J Clin Oncol; 1994 May; 12(5):895-8. PubMed ID: 8164039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.